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Abstract
Objectives—We have shown that, in a randomized trial comparing adherence to different 
colorectal cancer (CRC) screening strategies, participants assigned to either fecal occult blood 
testing (FOBT) or given a choice between FOBT and colonoscopy had significantly higher 
adherence than those assigned to colonoscopy during the first year. However, how adherence to 
screening changes over time is unknown.
Methods—In this trial, 997 participants were cluster randomized to one of the three screening 
strategies: (i) FOBT, (ii) colonoscopy, or (iii) a choice between FOBT and colonoscopy. Research 
assistants helped participants to complete testing only in the first year. Adherence to screening was 
defined as completion of three FOBT cards in each of 3 years after enrollment or completion of 
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colonoscopy within the first year of enrollment. The primary outcome was adherence to assigned 
strategy over 3 years. Additional outcomes included identification of sociodemographic factors 
associated with adherence.
Results—Participants assigned to annual FOBT completed screening at a significantly lower rate 
over 3 years (14%) than those assigned to colonoscopy (38%, P<0.001) or choice (42%, P<0.001); 
however, completion of any screening test fell precipitously, indicating the strong effect of patient 
navigation. In multivariable logistic regression analysis, being randomized to the choice or 
colonoscopy group, Chinese language, homosexuality, being married/partnered, and having a non-
nurse practitioner primary care provider were independently associated with greater adherence to 
screening (P<0.01).
Conclusions—In a 3-year follow-up of a randomized trial comparing competing CRC screening 
strategies, participants offered a choice between FOBT and colonoscopy continued to have 
relatively high adherence, whereas adherence in the FOBT group fell significantly below that of 
the choice and colonoscopy groups. Patient navigation is crucial to achieving adherence to CRC 
screening, and FOBT is especially vulnerable because of the need for annual testing.
Introduction
US guidelines recommend screening average-risk individuals for colorectal cancer (CRC) 
with one of the several tests (1,2), and colonoscopy and fecal occult blood testing (FOBT) 
are the most widely used methods. Each test has different characteristics in terms of efficacy, 
safety, cost, and tolerability, but both FOBT (3–6) and colonoscopy (7,8) have been shown 
to decrease CRC incidence and mortality. We previously reported that, after 1 year in a trial 
of competing CRC screening strategies, participants assigned to FOBT or given a choice 
between FOBT and colonoscopy had significantly higher adherence than those assigned to 
colonoscopy (9). In addition, we found differences in screening by race/ethnicity and 
language group. We were interested in examining the natural history of screening adherence 
after the conclusion of the interventional portion of the trial and whether racial/ethnic and 
linguistic differences would persist over time. Longitudinal adherence is particularly 
important for FOBT, as it should be repeated every 1–2 years, and the rate of attrition has 
important implications for the long-term effectiveness of this screening modality. In contrast, 
a single colonoscopy provides a high level of protection for up to 10 years. We present 
updated data on CRC screening adherence during the 3 years following initial enrollment.
Methods
Patients and study design
The study design of this cluster randomized trial has been previously described (9). In brief, 
997 participants at average-risk for CRC between 50 and 79 years of age were randomized 
to one of the three screening strategies: (i) three guaiac FOBT cards annually, (ii) 
colonoscopy, or (iii) a choice between annual FOBT and colonoscopy. Exclusion criteria 
included a history of CRC in a first degree relative, personal history of CRC, adenoma, or 
inflammatory bowel disease, presence of symptoms requiring endoscopy, having undergone 
appropriate CRC screening (FOBT within 1 year, sigmoidoscopy or barium enema within 5 
years, or colonoscopy within 10 years), medical comorbidity precluding endoscopy, or 
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estimated life expectancy of <10 years. Participants were identified from the San Francisco 
Community Health Network, a safety net public health system. Three research assistants 
fluent in the participants' preferred language—English, Spanish, Cantonese, or Mandarin—
obtained consent for participation in the trial, completion of a baseline survey, and follow-up 
through medical record review. Each research assistant attended multiple didactic sessions 
led by the principal investigator (J.M.I.), during which the risks and benefits of different 
screening strategies, barriers to screening, and strategies to increase adherence were 
extensively discussed. Research assistants were also trained to perform essential tasks of 
patient navigation, including explaining each CRC screening strategy in the preferred 
language of the participant, helping participants to schedule procedures, explaining bowel 
preparation instructions, arranging transportation after colonoscopy, and answering 
questions about the CRC screening tests (10), but they did not complete a formal patient 
navigation training program. FOBT cards were mailed to the research staff for assessment of 
adherence before being submitted for laboratory processing. Screening tests were provided 
regardless of insurance status or the ability to pay through “Healthy San Francisco.” 
Sociodemographic, health-related, and outcomes data were collected from the surveys and 
medical record. Additional follow-up for screening outcomes was conducted through 
medical record review and direct contact with participants to confirm non-completion of 
CRC screening tests. Because of the absence of funding, the research assistants did not assist 
with testing logistics after the initial year of enrollment. This study was approved by the 
institutional review board at the University of California, San Francisco, and the University 
of Washington. All authors had access to the study data and reviewed and approved the final 
manuscript.
Study outcomes
The primary outcome was adherence to the assigned screening strategy in the three study 
groups over the 3 years subsequent to enrollment. Adherence was defined as either annual 
FOBT for 3 years, with colonoscopy if FOBT was positive (FOBT strategy), or one 
colonoscopy during the first 12 months after enrollment (colonoscopy strategy). Individuals 
who completed a competing strategy before their assigned strategy were considered non-
adherent. In addition, we compared adherence among the study groups with two secondary 
outcomes: (i) biennial FOBT, defined as two FOBTs over 3 years, and (ii) any screening 
strategy, regardless of assigned group. Participants who did not complete any screening test 
within the first 12 months of enrollment were considered non-adherent for all analyses. We 
used multivariable logistic regression to identify predictors of adherence overall and, in a 
secondary analysis, stratified by the study group.
Statistical analysis
Adherence rates were compared pairwise using the χ2 test. Individuals with missing data 
were considered to be non-adherent. For logistic regression analysis, only variables with P-
values <0.05 on univariable analysis were entered into the multivariable model. To preserve 
model validity, we confirmed that the number of events per variable was >10 (11). All 
logistic regression analyses were adjusted for potential within-primary care provider 
clustering using a multilevel mixed-effects model. To adjust for multiple testing, results were 
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considered significant if the two-sided P-value was <0.01. Stata version 12.1 (StataCorp, 
College Station, TX) was used for all analyses.
Results
Participant characteristics
Of the 997 participants who had enrolled in the trial, 26 (3%) were lost to follow-up over 3 
years (Figure 1). Thirty-eight (4%) of the remaining 971 participants died, but none of the 
deaths were from CRC. The mean participant age was 58.4 years, and 53% were women 
(Table 1). This racially/ethnically diverse group comprised 34% Latino and 30% Asian 
participants, most of whom were Chinese. Linguistically, 55% of participants preferred 
English, 27% preferred Spanish, and 18% preferred Chinese. A majority (57%) of 
individuals had an annual household income under $10,000, 67% had completed at least a 
high school-level education, and 34% were employed. Baseline participant characteristics 
across study groups were generally similar, although a greater proportion of those in the 
FOBT group had nurse practitioners (NPs) as primary care providers (PCPs) and a greater 
proportion in the colonoscopy group was married/partnered.
Adherence to screening
In the FOBT and choice groups, a small proportion of participants who were considered 
non-adherent (4 and 7% in year 1; 5 and 5% in year 2; and 2 and 0% in year 3) returned 
guaiac cards but either performed the cards incorrectly or did not complete a colonoscopy 
after a positive result (Figure 1). Figure 2 shows each group's adherence to assigned 
screening strategy 1, 2, and 3 years after enrollment. In the FOBT group, 67% of individuals 
completed screening in the first year, 27% adhered to screening during both of the first 2 
years, and 14% remained adherent all 3 years. In the choice group, adherence was 69% 
during the first year (38% by the FOBT strategy), 49% over 2 years (18% by FOBT), and 
42% over all 3 years (12% by FOBT). Adherence in the colonoscopy group was 38% after 1 
year and by definition remained constant for all 3 years. As colonoscopy was still available 
to participants in the colonoscopy and choice arms, however, adherence was tracked, and 
only 10 additional patients (8 in the colonoscopy group, 2 in the choice group) completed 
the colonoscopy strategy over the next 2 years of follow-up. For the primary outcome of 
adherence to assigned screening strategy during 3 years, the FOBT group completed 
screening at a significantly lower rate than either the colonoscopy or the choice groups 
(P<0.001); adherence between the colonoscopy and the choice groups did not significantly 
differ (P=0.28).
When adherence to FOBT was defined as biennial testing, screening completion rates by 
assigned group were 39% in the FOBT group and 56% in the choice group. Under the 
biennial FOBT definition, adherence in the choice group was statistically higher than that in 
the FOBT and colonoscopy groups (P<0.001), whereas there was no difference between the 
FOBT and colonoscopy groups (P=0.85). The completion rate for any screening strategy 
irrespective of the strategy assigned/chosen, using the annual FOBT definition, was 16% in 
the FOBT group and 42% in both the colonoscopy and choice groups (Supplementary 
Figure 1 online). Using the biennial FOBT definition, adherence was 40% in the FOBT 
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group, 51% in the colonoscopy group, and 56% in the choice group. In both cases, 
adherence was significantly lower in the FOBT group than in the colonoscopy and the 
choice groups (P<0.01), and there was no statistical difference between the latter two groups 
(P>0.10). Cross-over FOBT use among colonoscopy group participants was higher than 
colonoscopy use among FOBT group participants, especially in the first 2 years.
Predictors of adherence
Neither of the two measures of immigration status we evaluated—being US-born (odds ratio 
(OR)=0.92, 95% confidence interval (CI): 0.66–1.29) and being a long-term immigrant vs. 
having immigrated within 7 years of enrollment (OR=1.09, 95% CI: 0.62–1.92)—were 
significant predictors of adherence. We included the nine socioeconomic and health-related 
variables that were significantly associated with adherence on univariable analysis in the 
multivariable model (Table 2). Assignment to the colonoscopy (OR=3.71, 95% CI: 2.34–
5.90) and choice (OR=4.81, 95% CI: 3.19–7.25) groups, preference for Chinese language 
(OR=2.91, 95% CI: 1.49–5.67), homosexuality (OR=4.25, 95% CI: 1.87–9.64), and being 
married/partnered (OR=1.70, 95% CI: 1.14–2.52) were independently associated with 
adherence. Conversely, compared with individuals with attending physician PCPs, those 
with NP PCPs were less adherent to screening (OR=0.43, 95% CI 0.23–0.81). Compared 
with the youngest age group, the 60–69 years age group (OR=1.49, 95% CI: 1.02–2.18) also 
showed a positive association with adherence, although this did not meet our pre-specified 
criterion for significance of P<0.01. We repeated univariable analyses to identify predictors 
of adherence to assigned screening strategy using the biennial FOBT definition, and nine 
significant variables were entered into the multivariable model. In the adjusted model, only 
choice group (OR=1.87, 95% CI: 1.28–2.73) and homosexuality (OR=3.68, 95% CI: 1.94–
6.99) remained significantly associated with adherence (Supplementary Table 1). Adherence 
did not differ depending on which research assistant performed patient navigation in either 
univariable or multivariable analyses. In addition, we performed sensitivity analyses without 
adjustment for clustering by PCP, and the direction and magnitude of associations remained 
unchanged.
Predictors of adherence were different when stratified by the study group (Supplementary 
Table 2). In the FOBT group, Chinese language (OR=12.73, 95% CI: 1.37–118.55) was the 
only variable that reached marginal significance in the adjusted model. Age 60–69 
(OR=3.33, 95% CI: 1.47–7.52) was the only significant predictor of adherence in the 
colonoscopy group. In the choice group, Chinese language (OR=4.14, 95% CI: 1.49–11.46) 
and homosexuality (OR=8.23, 95% CI: 2.88–23.49) were significantly associated with 
adherence.
Discussion
In this randomized trial of a racially/ethnically and linguistically diverse population, we 
found a substantial reduction in adherence to CRC screening over a 3-year period. Because 
of the need for annual or biennial screening, the FOBT strategy was most greatly impacted. 
Screening adherence remained highest in the choice group at each year of follow-up, 
although by 3 years there was no statistical difference between the choice and colonoscopy 
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groups. As the major difference between the initial and the subsequent 2 years of follow-up 
was the presence of research assistants, we assume that their role of patient navigation was 
crucial in achieving the high uptake seen in the initial year. Adherence was positively 
associated with assignment to the choice and colonoscopy groups, Chinese language, 
homosexuality, and being married/partnered and negatively associated with having NPs as 
PCPs.
Our study provides real-world adherence rates for longitudinal FOBT after an intervention. 
As participants did not receive assistance with test completion (patient navigation) after the 
first year, findings from the subsequent 2 years represent a natural history study of screening 
behavior when insurance or the ability to pay for screening is not a factor. We found a 
substantial reduction in adherence in both the FOBT group and the FOBT arm of the choice 
group, demonstrating consistent attrition to screening by FOBT across study groups. 
Furthermore, the decrease in adherence persisted after year 2 into year 3, which suggests 
that without intervention further attrition is likely. Previous interventional studies have 
reported longitudinal adherence rates for annual FOBT ranging from 38% in a randomized 
trial (12) to 55% in a population-based study (13), both of which also followed participants 
for 3 years. Notably, both of these studies used fecal immunochemical testing (FIT) rather 
than the guaiac tests used in our study, and studies have demonstrated 11–13% higher 
adherence to fecal immunochemical testing compared with guaiac FOBT (14,15). However, 
the Minnesota Colon Cancer Control Study also used annual guaiac FOBT and reported 
46% adherence over 11 screening cycles (3). A key difference between these three studies 
and ours is that the earlier studies all actively followed participants and facilitated screening 
by providing FOBT kits, and therefore these adherence rates do not reflect real-world 
scenarios where screening promotion and outreach is limited or unavailable. Our results are 
more consistent with findings from two community-based observational studies (16,17), 
which reported 25–44% adherence to a second round of FOBT among previously adherent 
individuals; in our study, 41% of participants in the FOBT group who were adherent in year 
1 remained adherent in year 2.
During the first year of the study, research assistants played a crucial role in helping 
participants complete the screening tests. Nearly half of the participants preferred Spanish or 
Chinese as the language of communication, and our research assistants functioned as 
language-concordant peer patient navigators for the purpose of the study. The withdrawal of 
these patient navigators after the first year of enrollment played a major role in the large and 
persistent attrition in screening by FOBT in years 2 and 3. Colonoscopy completion was also 
affected, but because of our definition of adherence (procedure must have been performed in 
the first year of the study) and the duration of colonoscopy effect on CRC prevention, this is 
not highlighted in our results. Nevertheless, because screening is recommended every 10 
years for colonoscopy and every 1 to 2 years for FOBT, patient navigation for colonoscopy 
is inherently less frequent than that for FOBT. Patient navigation has been shown to increase 
CRC screening among racial/ethnic minorities (18–20) and can produce sustainable 
improvement over time. In a study of longitudinal patient navigation over a 5-year period, a 
clinic serving low-income minorities and immigrants not only increased its overall screening 
rate from 49 to 69% but also nearly eliminated the deficit in screening compared with 
nearby practices (21). In addition, a patient navigator program in another urban public 
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hospital system serving low-income minorities showed that not only was the program cost-
effective but also that it can yield a financial benefit to providers (22). Therefore, peer 
patient navigation may be a cost-effective strategy to maintain a high level of adherence in a 
CRC screening program, especially in a racially/ethnically and linguistically diverse 
population.
Whereas US guidelines (1,2) recommend screening by FOBT on an annual basis, screening 
programs in Canada (23) and 19 member nations of the European Union (24) use biennial 
testing. Randomized trials from both the US and Europe have shown that biennial FOBT 
also reduces CRC mortality (4,5,25). In these trials, in which participants received reminders 
to undergo FOBT, adherence through three to six cycles of biennial screening ranged from 
38 to 60%. Adherence to biennial FOBT in our study was 39% through only two cycles of 
screening and would be expected to decrease with additional follow-up, which again 
demonstrates that attrition to CRC screening in clinical practice is much greater than 
previously appreciated. These results are critically important as the benefits of FOBT are 
estimated to be similar to endoscopic methods only if there is very high longitudinal 
adherence to the FOBT strategy (26). Among European countries that utilize biennial FOBT 
for population-based screening, participation ranges from 20% in the Czech Republic to 
52% in the UK and to 71% in Finland (27). Applying the attrition rate for biennial FOBT 
from our study, the projected adherence to the FOBT screening strategy over 2 cycles of 
testing would be 12% in the Czech Republic, 30% in the UK, and 41% in Finland. These 
projected rates are clearly suboptimal, and therefore monitoring and maintenance of 
longitudinal adherence to FOBT will be especially important in most non-US nations where 
FOBT is the only available strategy for average-risk CRC screening.
Participants who were offered a choice between colonoscopy and FOBT continued to have 
the highest rate of adherence at 3 years of follow-up, despite encountering a level of attrition 
that was comparable to the FOBT group. In addition, a number of participants assigned to 
the FOBT and colonoscopy groups opted for the competing strategy, which reinforces the 
value of choice. As our initial study and others have shown, offering individuals a choice of 
screening tests is an important strategy to increase overall screening rates (9,28). The choice 
strategy may be particularly effective for countries that offer screening through both biennial 
FOBT and colonoscopy, such as Austria, the Czech Republic, and Germany, as we found it 
led to significantly higher adherence than either biennial FOBT or colonoscopy.
National screening rates among Asians (46%) are the lowest of any racial/ethnic group in the 
United States (29), and a study in California showed that Chinese have one of the lowest 
screening rates among Asian ethnic subgroups (30). Therefore, our finding that Chinese 
speakers were significantly more likely to adhere to screening is unexpected. Greater 
duration of residency among Asian immigrants has been associated with increased CRC 
screening (31), but in our study there was no difference between US-born and immigrant 
participants overall or between recent and long-term immigrants. Rather, as adherence 
among Spanish speakers was also higher than that of the reference English group, these 
results suggest that peer navigation may have enabled linguistic minorities to overcome the 
language barrier to health-care access. Indeed, studies show that patient navigation is 
especially effective for non-English speakers (21,32). Although both language and race/
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ethnicity were significant predictors of adherence in unadjusted analysis, only language 
remained significant in the full model. This suggests that language may be a more reliable 
measure of cultural influences on health behavior than race/ethnicity, especially in 
immigrant populations.
We found a strong association between homosexuality and screening adherence, and nearly 
all homosexual participants in our study were men. State-level surveys have either found a 
positive association (33) or no association (34) between male homosexuality and CRC 
screening, and our study is the first randomized trial to report this relationship. Given the 
small sample size in our study—only 10% of participants were homosexual—it would be 
premature to speculate on potential social or medical reasons for this observed difference, 
but future research is warranted. Our finding that married/partnered individuals were more 
likely to be adherent to screening is consistent with previous studies and indicates the 
importance of social support in the utilization of preventive care (35–37).
We also found that participants under the care of NPs were significantly less likely to be 
adherent to CRC screening than those under the care of attending physicians, and reduced 
screening was seen consistently in all three study groups. Lower CRC screening rates for 
patients of NPs have been reported previously (38,39) as has lack of knowledge about 
screening guidelines among NPs (39). In contrast, nurse-led care compares favorably with 
physician-led care in hypertension management, hospitalization rates, and overall mortality 
(40,41). This apparent discrepancy may reflect the relative complexity of CRC screening 
guidelines or that NPs prioritize other more widely-accepted quality measures in primary 
care. Expanded health-care coverage under the Affordable Care Act will increase the 
number of NPs in primary care, and greater emphasis on CRC education is needed to ensure 
a high level of screening.
The stratified analysis of predictors of adherence by the study group showed some 
interesting differences between the three groups and the combined results. Specifically, 
language did not predict adherence in the colonoscopy group, and homosexuality was only 
associated with adherence in the choice group. However, although it is plausible that 
predictors of adherence may be different for each screening strategy, the wide confidence 
intervals seen in this secondary analysis indicate that our study was not adequately powered 
to address this question, and we would caution against overinterpreting these results.
We acknowledge several study limitations. First, as our study was not designed to evaluate 
patient navigators, our research assistants were not formally trained as such. However, 
training for patient navigation is not standardized, and our research assistants performed 
nearly all the patient navigator tasks assessed by the Centers for Disease Control and 
Prevention's Colorectal Cancer Control Program (42). Therefore, we believe that the 
research assistants fulfilled the role of patient navigators in this study. Second, we cannot 
exclude the possibility that attrition in adherence to the FOBT strategy was due to 
unmeasured patient or provider factors rather than the withdrawal of patient navigation. 
Patients may have felt abandoned by the withdrawal of resources and consequently become 
less adherent, as health provider recommendation and social support are both associated 
with increased adherence (43). Nevertheless, the higher rates of serial FOBT screening 
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reported in other studies suggest that patient navigation and reminders can offset attrition to 
screening by FOBT. Finally, the racial/ethnic and linguistic diversity of our participants may 
limit the generalizability of our findings. However, given the rapidly evolving demographic 
landscape in the United States, health concerns pertaining to minorities will become 
increasingly more important to the general populace, as the proportion of racial/ethnic 
minorities continues to grow.
In summary, in a trial of competing CRC screening strategies, participants who were given a 
choice between FOBT and colonoscopy maintained the highest rate of adherence after 3 
years of follow-up. Adherence decreased sharply for participants randomized to the FOBT 
strategy after the withdrawal of patient navigation. Patient navigation appears to be 
especially effective for racial/ethnic and linguistic minorities and may be an important 
intervention to achieve and sustain a high level of CRC screening.
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Study Highlights
What is Current Knowledge
• Individuals who are offered one-time colorectal cancer (CRC) screening with a 
fecal occult blood test (FOBT) or a choice between FOBT and colonoscopy 
have higher rates of test completion than those offered colonoscopy alone.
• Adherence rates over time to these competing screening strategies are unknown 
but are important for establishing the programmatic effectiveness of each 
strategy.
• Racial/ethnic minorities and non-English speakers have lower prevalence of 
CRC screening, but these disparities may be reduced by patient navigation.
What is New Here
• Without a mechanism to maintain adherence to screening, adherence to FOBT 
over 3 years was significantly lower than to colonoscopy alone or a choice 
between FOBT and colonoscopy.
• Following a limited period of patient navigation, there were no racial/ethnic 
differences in CRC screening, and non-English speakers were more likely to 
complete screening than English speakers.
• These data suggest that patient navigation may be helpful in maintaining both 
long-term adherence to CRC screening and reducing disparities.
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Figure 1. 
Study flowchart. Number of individuals who completed the strategy is cumulative and 
indicates adherence to assigned group through the time of follow-up. Number of individuals 
who did not complete the strategy is non-cumulative and indicates data for one year.
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Figure 2. 
Adherence to assigned colorectal cancer screening strategy. Adherence in the choice group 
is shown in the third bar of each follow-up period.
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